Earnings Call Insights: Roivant Sciences Ltd. (ROIV) Q4 2025
Management View
CEO Matthew Gline said the quarter included “the preliminary open-label period data from the 1402 study in D2T RA” and a “planned spotlight… on mosliciguat,” alongside “some smaller updates on the brepocitinib program.”
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
